This indefinite delivery contract (IDC) was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency under the National Institutes of Health (NIH), to Bioqual, Inc., a for-profit biomedical research services company located in Rockville, Maryland. The $136.6 million single-award IDC has an ultimate completion date of September 29, 2035 and will provide evaluation and testing services (ETS) for vaccines and other biologics for infectious diseases. Bioqual,...
This indefinite delivery contract (IDC) was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the Department of Health and Human Services, to the American Foundation For Biological Research, doing business as the Biomedical Research Institute. The $146.3 million single-award IDC has a period of performance from July 15, 2024 to July 14, 2031. The purpose of this IDC is to provide NIAID with the capability and capacity to develop and employ...
This indefinite delivery contract (IDC) was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to The Charles Stark Draper Laboratory, Inc. (Draper) for the development and employment of animal and animal replacement models of infectious diseases. The $146.3 million single-award IDC has a 7-year ordering period and supports the full range of preclinical evaluations, including screening, product evaluation, and eventual clinical evaluation of...
This indefinite delivery contract (IDC) was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to Bioqual, Inc., a for-profit biomedical research services company, to support the Simian Vaccine Evaluation Units (SVEU) program. The $66,355,351.00 IDC, which has an ultimate completion date of March 31, 2027, provides a vehicle for NIAID to issue delivery orders to Bioqual for conducting specialized research studies, providing laboratory analysis, and...
The National Institute of Allergy and Infectious Diseases (NIAID) has awarded a single-award, $146.3 million Indefinite Delivery Contract (IDC) to The Research Foundation For The State University Of New York to develop and employ animal and animal replacement models of infectious diseases for screening, product evaluation, and eventual clinical evaluation. This IDC contains four task areas: Task Area A - Small Animal Models of Infectious Diseases Task Area B - Non-Human Primate Models of...
This Indefinite Delivery Contract (IDC) was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency under the Department of Health and Human Services, to Emory University, a private research university. The contract has a ceiling value of $146,300,000 and a period of performance through July 2031. The purpose of this IDC is to provide NIAID with the capability to develop, refine, and employ small animal models, non-human primate models, animal...
The National Institute of Allergy and Infectious Diseases (NIAID) has awarded a $146.3 million single-award Indefinite Delivery Contract (IDC) to the UK Health Security Agency (formerly Public Health England) to provide preclinical services in support of the development of medical countermeasures against chemical, biological, radiological, and nuclear threats. The contract includes task areas for small animal models, non-human primate models, animal replacement and non-traditional animal models,...
This indefinite delivery contract (IDC) was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian federal agency, to The Trustees of the University of Pennsylvania (Penn) for the development and use of animal and animal replacement models to evaluate candidate countermeasures (vaccines, therapeutics, diagnostics) against infectious diseases. The $146.3 million single-award IDC has a 7-year ordering period and covers four task areas: (A) small animal models, (B)...
The Indefinite Delivery Contract (IDC) 75N93024D00028 was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the U.S. Department of Health and Human Services, to the University of Tennessee, a non-profit educational institution. The $146.3M contract has an ordering period ending in July 2031 and covers the development and use of animal and animal replacement models to evaluate candidate countermeasures (e.g., therapeutics, vaccines,...
The National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency of the U.S. Department of Health and Human Services, awarded a $146.3 million Indefinite Delivery Contract (IDC) to Institute For Clinical Pharmacodynamics, Inc., a for-profit organization, to provide pre-clinical models of infectious diseases under Task Area C. The period of performance is from July 15, 2024 to July 14, 2031. The contract is a follow-on to a previous Preclinical Models of Infectious Diseases...
This indefinite delivery contract (IDC) was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian federal agency, to Bioqual, Inc. as the prime contractor. The $146.3 million, single-award IDC has a 7-year period of performance and will support the development and refinement of animal and animal replacement models to evaluate candidate countermeasures (e.g. vaccines, therapeutics, diagnostics) against a range of infectious diseases, including those with pandemic potential. The contract is divided into four task areas: (A) small animal models, (B) non-human primate models, (C) animal replacement and non-traditional animal models, and (D) generation and distribution of specialized reagents. Bioqual, as a fully accredited research services provider, will conduct animal studies, provide laboratory analysis, and support housing and care of research animals to further NIAID's mission of understanding, treating, and preventing infectious diseases.